Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus Oncolytic virotherapy is a tumour-specific strategy, in which viruses selectively kill cancer cells, either through targeted alterations in the cancer cell, 1,2 viral deletions, 3, 4 tissue-specific transcriptional control 5 or tumour-specific receptors. 6, 7 Normal cells are generally left intact. Haematologic malignancies such as multiple myeloma (MM) are particularly attractive for this approach as patients generally have less bulky disease and may have immune system dysfunction favouring viral replication. To date, MM has demonstrated pre-clinical responses to oncolytic measles virus, 6 ,7 vesicular stomatitis virus 8 and coxsackievirus A21. 9 Our lab has previously developed an attenuated, recombinant double-deleted vaccinia virus (VV) that infects, replicates and expresses genes preferentially in rapidly dividing tumour cells. 4 We asked whether VV would be an effective oncolytic virus against MM.
Initially, fluorescence-activated cell sorting analysis was used to quantitate the percentage of enhanced green fluorescent protein (EGFP)-positive MM cells after infection with an EGFPexpressing VV. All five cells lines were infected (Figure 1a) . After 72 h, RPMI8226 was most efficiently infected and U266 was the least efficient. To confirm that VV infection and gene expression in MM cell lines led to oncolysis and cell death, MM cell lines were infected with VV at a multiplicity of infection (MOI) of 1, and MTT assays were performed (Figure 1b ). Compared to mockinfected controls (100% viable), all cell lines showed decreased viability from 17 to 29% at 72 h. To validate the MTT assays, a trypan blue exclusion assay was performed with similar results (Supplementary Figure S1) . In vitro oncolysis, as measured by an assay to detect cytopathic effects, was visible by 48 h (Figure 1c) after infection for the majority of cell lines. This was delayed for the U266 and H929 cell lines suggesting that these cell lines are less susceptible to VV-mediated cell killing though both were infected and express EGFP (Figure 1c, bottom panel) .
As many anti-myeloma therapeutics act through the induction of apoptosis in MM cells, we asked whether VV-mediated cell death was due to a similar mechanism. Annexin V staining was used to quantitate the number of cells undergoing apoptosis. Compared to mock infection alone, VV infection induced apoptosis in four of five cell lines by 72 h (Supplementary Figure S2) . The number of necrotic cells was also increased over mock infection.
We next evaluated VV-mediated oncolysis in established tumours after systemic delivery. My5 subcutaneous xenograftbearing mice were treated with systemic (intraperitoneal, 10 9 plaque-forming unit (PFU) per mouse) VV or vehicle control. After treatment with a single dose of VV, the growth of My5 (Figure 2a ) xenografts was significantly (Po0.0001) inhibited by the treatment compared to vehicle control. In addition, My5-bearing mice re-treated with a second dose of VV showed further tumour regression. Selected mice underwent fluorescent imaging at various time points after infection with the EGFPexpressing VV. Viral-mediated EGFP expression was minimal 6 days after VV infection, but slowly spread throughout the tumour and peaked 3 weeks post-infection (Figure 2b ).
In the setting of haematologic malignancies, where malignant cells are wide spread, the ability to deliver a systemic therapy that can target all tumour cells is critical. The most remarkable response we saw was in the treatment of a model of systemic MM. 10 This is a murine model that closely resembles the human disease, in which MM cells lodge in the spine and skull after intravenous delivery. In untreated mice, this model results in paralysis within 3 weeks. Nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice were irradiated and injected with RPMI8226 cells via tail vein. Groups of mice were treated with intraperitoneal VV or vehicle control on day 3 or 7 after tumour injection. VV was very effective in this setting. As seen in Figure 2c , mice receiving the vehicle control died with a median survival of 15 days. Mice receiving VV on day 7 had an intermediate survival of 26 days (median). Of mice treated 3 days after tumour injection, 80% were alive and well more than 100 days after tumour injection (Po0.01).
To confirm that systemic delivery of VV resulted in tumourspecific viral replication, other mouse tissues were analysed. Twenty-one days after VV injection, mice were euthanized and tissues analysed for live virus content by plaque assay. In agreement with the EGFP imaging, tumour was the site of maximum viral replication with a 4-log increase over the next highest tissue (ovary) and a 3-log increase over the total injected dose, confirming viral replication in the tumour (Supplementary Figure S3) . Minimal live virus was recovered from other organs. Tissues from these mice were also examined by a pathologist (CM) for evidence of any histopathological change in selected nontumour tissues. With the exception of ovary (Figure 2d ), which had evidence of necrosis from presumed viral replication, no other tissues showed any evidence of histopathological lesions or changes consistent with toxicity or adverse reaction. In particular, brain, liver and bowel were normal (Figure 2d ). No evidence of histopathological changes in the bone marrow were apparent.
Finally, we investigated the ability of VV to infect primary bone marrow mononuclear cells of patients with MM and peripheral blood mononuclear cells (PBMCs) from normal volunteers. Cells were infected with a low viral MOI, and significant rates of infection were seen in the malignant MM cells. As seen in Figure 3a (and Supplementary Table S1 ), 50-75% of the CD138 þ cells expressed VV-mediated EGFP 72 h after infection, in the majority of MM patients tested. Only one patient had a low level (4%) of CD138 þ cell infection. Surrounding normal cells were relatively uninfected. PBMCs of normal donors demonstrated very low levels of infectivity. Seventy-two hours postinfection, minimal numbers of cells showed viral EGFP expression (Figure 3b) . Fluorescenceactivated cell sorting analysis to determine the cell populations that were infected showed an overall infectivity of normal PBMCs of 1-2% after 72 h; however, specific populations of lymphocytes were much less (CD3 þ : 0.03±0.03%; CD19 þ : 0.16 ± 0.12%; Figure 3c ).
Here we have presented the first evidence that MM responds well to systemic VV therapy and should be considered for further development. Recent strategies for MM have focused on targeting the malignant cells themselves while avoiding the toxicities associated with traditional chemotherapeutics. We found that VV kills the malignant plasma cells very well, and the tumour specificity of a double-deleted VV is maintained in models of MM. Although this tumour specificity is thought to be due to substrates (such as thymidine triphosphate) present in dividing cancer cells, 4 MM cells may provide an added advantage to VV replication.
Toxicity to normal tissues is a concern when using a replicating oncolytic virus; however, no toxicities were observed in this study. In fact the 4-log difference in viral replication noted between the tumour and normal tissues provides a wide therapeutic window within which to treat these patients.
One remaining variable is the robust immune response generated to VV, 11 which may limit effective treatment to one dose. The immune response may also provide a benefit in that tumour cells infected with the virus will be lysed and can potentially present tumour-specific antigens for recognition by the immune system. Given the enhanced in vivo versus in vitro responses seen, we expect that some degree of the tumour response will prove to be immune-mediated. 
